(NASDAQ: ENSC) Ensysce Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 22.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Ensysce Biosciences's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ENSC's revenue for 2026 to be $101,920,997, with the lowest ENSC revenue forecast at $97,924,095, and the highest ENSC revenue forecast at $104,918,673.
In 2027, ENSC is forecast to generate $1,308,720,847 in revenue, with the lowest revenue forecast at $1,257,392,986 and the highest revenue forecast at $1,347,220,416.